- Home
- NSTS vs INKT Comparison
NSTS vs INKT Comparison
Compare NSTS & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NSTS | INKT |
|---|---|---|
| Founded | 1921 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.8M | 53.1M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NSTS | INKT |
|---|---|---|
| Price | $11.70 | $11.15 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | 6.8K | ★ 66.3K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $252,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.73 | $6.66 |
| 52 Week High | $13.06 | $76.00 |
Technical Indicators
Market Signals| Indicator | NSTS | INKT |
|---|---|---|
| Relative Strength Index (RSI) | 47.23 | 56.42 |
| Support Level | $11.48 | $10.94 |
| Resistance Level | $12.38 | $11.65 |
| Average True Range (ATR) | 0.25 | 0.93 |
| MACD | 0.02 | 0.23 |
| Stochastic Oscillator | 49.32 | 73.94 |
Price Performance
Historical ComparisonAbout NSTS NSTS Bancorp Inc.
NSTS Bancorp Inc is a savings and loan holding company regulated Federal Reserve Board. The company was formed to serve as the North Shore Trust and Savings stock holding company. The Bank is a wholly-owned subsidiary of the company and operates as a traditional savings institution focused on serving the banking needs of customers in market area of Lake County, Illinois and adjacent communities.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.